Immunostaining of surgical specimen however [19], could show over-expression of EGFR in adenoid cystic carcinoma in high percentages hence implying use of targeted therapies as potential alternative [19,20] to comparatively toxic chemotherapy regimen commonly used in recurrent or metastatic adenoid cystic carcinoma since the mid 80-ies [21-24]. The gene discussed is EGFR; the disease is adenoid cystic carcinoma.